Home Data Calendar Blog

MGNX

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Common Stock Value 0.620.620.620.620.610.610.610.610.610.600.600.560.560.530.490.490.490.490.490.420.420.420.370.370.370.370.350.350.350.350.340.340.340.300.300.280.280.280.270.250.02NANA0.01NANANA
Weighted Average Number Of Diluted Shares Outstanding NA62.2661.81NA61.4661.3861.32NA61.1760.0757.20NA54.4650.02NANANANANANANA42.1536.94NA36.7835.7834.96NA34.7736.0234.50NA33.3430.0631.68NA27.7527.6526.26NA21.241.221.15NA21.50NANA
Weighted Average Number Of Shares Outstanding Basic NA61.8861.81NA61.4661.3861.32NA61.1760.0757.20NA54.4650.02NANANANANANANA42.1536.94NA36.7835.7834.96NA34.7734.6234.50NA33.3430.0629.42NA27.7527.6526.26NA1.181.221.15NA1.09NANA
Earnings Per Share Basic 0.280.93-0.610.21-0.40-0.67-1.08-0.95-0.86-0.66-0.900.02-0.66-0.94NANANANANANANANANA2.87-1.28-1.14-1.08-1.00-0.971.17-0.88-0.83-0.46-0.711.53-0.69-0.14-0.44-0.12-0.140.14-0.24-2.93-1.920.000.000.00
Earnings Per Share Diluted 0.280.92-0.610.21-0.40-0.67-1.08-0.95-0.86-0.66-0.900.02-0.66-0.94NANANANANANANANANA2.80-1.28-1.14-1.08-1.00-0.971.12-0.88-0.83-0.46-0.711.42-0.69-0.14-0.44-0.12-0.140.01-0.24-2.93-1.920.000.000.00

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Revenues 10.4013.1424.5073.1041.7326.0111.1014.1515.6630.7616.8852.6918.2520.2613.6825.1918.7410.599.6615.7920.8018.834.70152.361.661.672.065.113.2580.672.858.1814.686.7271.285.4818.389.2214.7214.9120.2312.3010.609.8016.0817.4320.51
Cost Of Goods And Services Sold 0.090.260.110.123.010.180.050.951.670.020.02NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Costs And Expenses 45.9058.1062.9261.1266.6967.8177.7472.3868.6571.0468.1754.8654.3967.5759.1363.8556.6963.5657.2857.4755.8063.1554.9147.3949.3942.8440.2640.3437.5240.5833.4836.7630.1228.0126.1524.5022.3121.4817.8318.1113.0712.5513.9312.0613.48NANA
Research And Development Expense 30.1343.2345.8745.6548.1951.7461.4455.8549.8255.7853.1242.3044.6657.3548.8951.9644.8551.4447.0646.9246.2252.0145.6738.9940.9834.4632.8031.1130.3033.3427.3530.0424.1022.6621.4619.6518.6317.3414.5714.3511.0911.0510.108.5111.97NANA
General And Administrative Expense 12.4113.6913.5313.6715.3613.6716.2515.5817.1615.2315.0412.569.7310.2210.2311.8911.8312.1210.2210.559.5811.139.238.408.408.387.469.237.227.246.136.716.025.354.684.843.684.143.263.761.991.503.833.551.51NANA
Operating Income Loss -35.50-44.96-38.4311.98-24.95-41.81-66.64-58.24-52.99-40.28-51.29-2.17-36.13-47.31-45.45-38.66-37.94-52.97-47.62-41.68-35.00-44.31-50.21104.97-47.72-41.18-38.21-35.24-34.2740.09-30.63-28.58-15.44-21.2945.13-19.02-3.93-12.26-3.11-3.217.16-0.25-3.33-2.262.60NANA
Interest Expense 0.000.77NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Allocated Share Based Compensation Expense 4.794.394.834.745.125.305.275.416.366.075.295.265.835.094.495.495.404.883.804.354.57NANANANANANANANANANANANANANANANANANA0.470.14NANA0.210.21NANA
Net Income Loss 17.5557.47-38.0112.80-24.81-41.30-66.44-58.02-52.89-39.94-51.27-2.09-36.04-46.88-44.72-30.40-44.63-31.77-45.02-44.64-34.03-43.24-49.54105.73-47.04-40.65-37.66-34.78-33.8540.46-30.36-28.45-15.44-21.3845.13-19.02-3.93-12.26-3.11-3.216.60-0.29-3.37-2.102.603.554.32
Comprehensive Income Net Of Tax 17.5957.39-38.0012.91-24.60-41.35-66.67-58.08-52.89-39.95-51.25-2.10-36.06-46.94-44.67-30.40-44.64-31.73-45.01NANANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Assets 339.97305.65343.50280.47195.35218.04271.44335.25392.16425.91435.44378.74374.38327.59265.41312.50351.45383.68414.64332.13355.36386.89326.08373.88241.84274.85274.72311.26339.86368.85325.66359.27384.09254.20278.07173.89193.62205.72210.17125.7841.98NANA53.75NANANA
Liabilities 145.99134.11234.23138.4672.3975.5693.2395.63100.72106.8784.9182.8682.8079.8174.8481.8796.2589.2394.0289.2572.7174.8678.8074.6452.3843.5040.0842.5139.7638.8739.4045.9344.7642.5147.0852.6054.5463.7456.9546.8746.02NANA61.98NANANA
Liabilities And Stockholders Equity 339.97305.65343.50280.47195.35218.04271.44335.25392.16425.91435.44378.74374.38327.59265.41312.50351.45383.68414.64332.13355.36386.89326.08373.88241.84274.85274.72311.26339.86368.85325.66359.27384.09254.20278.07173.89193.62205.72210.17125.7841.98NANA53.75NANANA
Stockholders Equity 193.98171.54109.27142.01122.96142.48178.21239.62291.44319.05350.53295.88291.58247.78190.57230.63255.20294.45320.62242.88282.64312.04247.28299.24189.47231.35234.64268.75300.10329.98286.25313.34339.33211.69230.99121.29139.09141.98153.2278.91-4.05NANA-8.24NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Assets Current 291.32254.68288.94222.18147.81167.63218.20279.56334.70367.00374.72312.59310.07260.20195.28239.78276.23287.60335.03269.12285.64322.05271.04322.30209.47250.11251.01283.95316.29348.44309.27342.38370.50242.43268.47164.74186.96198.76202.40119.4636.95NANA49.93NANANA
Cash And Cash Equivalents At Carrying Value 89.90108.76224.26108.8883.9921.4747.33123.47190.53188.97218.50181.13201.64196.5393.06126.47156.59180.32238.64220.13201.81238.66200.45211.7390.88116.6340.5284.10109.9062.27151.95196.17365.77235.03263.13157.59179.19194.01198.72116.4833.5733.7843.5347.7430.45NANA
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 89.90108.76224.26108.8883.9921.4747.33123.47190.53188.97218.50181.13201.64196.5393.06126.47156.59180.32238.64220.13201.81NANA211.73NANANA84.10NANANANANANANANANANANANANANANANANANANA
Accounts Receivable Net Current 25.316.4136.1656.2213.8418.3914.9010.3913.7645.257.1523.0818.7819.2011.8112.749.505.616.1229.5820.9717.847.2813.642.191.992.092.763.0178.382.511.222.744.331.722.945.322.651.752.002.28NANA2.05NANANA
Inventory Net 1.071.441.411.451.092.954.604.393.986.486.17NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Inventory Finished Goods 1.071.221.201.040.880.720.870.460.28NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Prepaid Expense And Other Assets Current 8.516.479.7210.169.2712.5614.7121.1718.0617.9618.2216.98NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Available For Sale Securities Debt Securities 166.53131.5917.3945.4639.62112.27136.66120.15108.37108.35124.6891.4079.0236.2777.7989.2886.2891.8281.75NA58.3462.2359.6393.39112.76127.03207.56200.88204.22203.36152.50142.88NANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Property Plant And Equipment Gross NANANA113.66NANANA110.48NANANA103.78NANANA97.94NANANA94.65NANANA78.90NANANA43.78NANANA35.03NANANA24.14NANANA20.5719.64NANA17.61NANANA
Construction In Progress Gross NANANA0.36NANANA0.63NANANA2.02NANANA0.19NANANA0.22NANANA32.80NANANA0.00NANANANANANANANANANANANANANANANANANANA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NANANA84.08NANANA72.81NANANA61.55NANANA49.73NANANA37.94NANANA28.92NANANA25.82NANANA20.19NANANA17.36NANANA15.5315.17NANA14.34NANANA
Property Plant And Equipment Net 22.6324.0926.7829.5731.9934.0236.0337.6838.6839.4040.4842.2341.4243.8946.3248.2149.9752.3054.8256.7158.6557.4953.4449.9830.8423.1817.3817.9618.4718.2914.3514.8411.539.417.246.795.635.445.085.044.47NANA3.27NANANA
Other Assets Noncurrent 1.391.391.381.3815.5416.3917.2118.0118.7819.5220.2523.9222.8923.5123.8124.5025.2543.7824.796.2911.067.351.601.601.541.551.361.372.102.112.042.042.062.062.062.060.731.112.280.890.15NANA0.15NANANA
Available For Sale Debt Securities Amortized Cost Basis 166.57131.6617.3845.4739.74112.60136.94120.21108.37108.34124.6791.4179.0236.2577.7289.2786.2591.7981.75NA58.3462.2259.6693.45112.79127.11207.67200.97204.21203.30152.44142.88NANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Liabilities Current 51.2945.1645.6148.6150.0550.8867.1074.5868.8669.9253.0450.6750.1245.8939.6145.1757.6349.5351.7759.9448.0248.0349.9649.7632.4429.8926.5527.3022.0519.5317.8123.2922.3923.8524.1327.0925.9929.8729.3828.8225.27NANA29.73NANANA
Accounts Payable Current 3.303.793.764.904.622.613.7315.506.179.8210.358.034.382.771.964.312.540.860.934.000.991.7710.272.451.682.091.514.001.371.151.122.972.541.851.441.674.393.985.133.171.80NANA3.74NANANA
Accrued Liabilities Current 25.4827.5328.1929.0033.3231.7632.9733.7641.8639.1734.9734.2032.6730.4825.0627.1428.3930.4128.8533.0238.4837.1830.4938.5825.5022.3217.9616.1315.3712.349.6911.719.128.307.007.934.033.312.743.580.94NANA1.24NANANA
Contract With Customer Liability Current 18.589.679.259.997.0811.5625.5620.6516.3116.573.524.469.269.279.5110.7023.5714.4518.0921.72NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Other Liabilities Noncurrent 0.260.260.260.260.260.260.260.260.260.260.26NA2.251.440.520.00NANANANANANANANANANANANA0.730.730.730.00NANANANANANANANANANANANANANANA
Operating Lease Liability Noncurrent 30.1830.1630.1330.1117.0018.2619.5120.7922.0223.2124.3525.2624.6525.6526.6127.5528.5824.2825.040.00NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Stockholders Equity 193.98171.54109.27142.01122.96142.48178.21239.62291.44319.05350.53295.88291.58247.78190.57230.63255.20294.45320.62242.88282.64312.04247.28299.24189.47231.35234.64268.75300.10329.98286.25313.34339.33211.69230.99121.29139.09141.98153.2278.91-4.05NANA-8.24NANANA
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 193.98171.54109.27142.01122.96142.48178.21239.62291.44319.05350.53295.88291.58247.78190.57230.63255.20294.45320.62242.88282.64312.04247.28299.24NANANANANANANANANANANANANANANANANANANANANANANA
Common Stock Value 0.620.620.620.620.610.610.610.610.610.600.600.560.560.530.490.490.490.490.490.420.420.420.370.370.370.370.350.350.350.350.340.340.340.300.300.280.280.280.270.250.02NANA0.01NANANA
Additional Paid In Capital Common Stock 1250.071245.231240.351235.101228.951223.881218.261213.001206.741181.471173.011067.151060.76980.92876.82872.20866.37860.98855.42732.73727.85723.20615.28611.27607.19602.09564.77561.20557.67553.65550.41547.18544.72401.68NA335.07NANANANANANANANANANANA
Retained Earnings Accumulated Deficit -1056.68-1074.23-1131.70-1093.69-1106.50-1081.68-1040.38-973.94-915.91-863.03-823.09-771.82-769.73-733.69-686.81-642.08-611.69-567.05-535.29-490.27-445.63-411.60-368.36-312.34-418.07-371.02-330.37-292.71-257.93-224.09-264.55-234.19-205.74-190.29-168.92-214.05-195.03-191.10-178.84-175.73-172.53NANA-175.47NANANA
Stock Issued During Period Value New Issues 0.190.230.62NANANANANA19.64NA98.20NA73.9896.51NANANANA118.66NANA103.26NANANANANANANANANANANANANANANANANANANANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 4.754.444.79NA5.085.355.22NA6.316.115.24NA5.805.144.45NA5.354.933.75NA4.524.213.39NANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Operating Activities -35.25-2.09-12.8329.32-9.42-49.16-57.70-54.31-14.79-45.69-29.04-5.53-25.68-36.55-44.14-38.04-17.39-48.84-30.00-27.23NANANANANANANANANANANANANANANANANANANA-1.18NANANA17.70NANANA
Net Cash Provided By Used In Investing Activities -33.52-113.4828.09-5.7971.9523.04-18.48-13.55-2.6213.82-34.26-16.07-43.2841.0110.567.63-6.37-10.12-70.4945.07NANANANANANANANANANANANANANANANANANANA-0.92NANANA-0.41NANANA
Net Cash Provided By Used In Financing Activities 49.910.06100.121.360.000.260.040.8018.972.35100.661.1074.0699.020.160.300.040.63119.000.47NANANANANANANANANANANANANANANANANANANA85.02NANANA0.00NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Operating Activities -35.25-2.09-12.8329.32-9.42-49.16-57.70-54.31-14.79-45.69-29.04-5.53-25.68-36.55-44.14-38.04-17.39-48.84-30.00-27.23NANANANANANANANANANANANANANANANANANANA-1.18NANANA17.70NANANA
Net Income Loss 17.5557.47-38.0112.80-24.81-41.30-66.44-58.02-52.89-39.94-51.27-2.09-36.04-46.88-44.72-30.40-44.63-31.77-45.02-44.64-34.03-43.24-49.54105.73-47.04-40.65-37.66-34.78-33.8540.46-30.36-28.45-15.44-21.3845.13-19.02-3.93-12.26-3.11-3.216.60-0.29-3.37-2.102.603.554.32
Depreciation Depletion And Amortization 1.952.812.983.232.842.882.912.952.802.782.732.892.963.302.812.732.642.582.903.012.731.201.341.341.912.001.981.972.081.791.77NANANANANANANANA0.370.32NANA0.280.24NANA
Increase Decrease In Accounts Receivable 18.90-29.75-20.0642.38-4.553.484.52-3.37-31.4938.10-15.934.30-0.437.40-0.943.243.89-0.50-23.478.613.1310.55-6.3611.450.20-0.10-0.67-0.24-75.3775.861.29-1.52-1.592.62-1.22-2.382.670.90-0.26-0.28-1.871.830.28-4.07NANANA
Increase Decrease In Inventories -0.380.03-0.040.36-0.06-0.570.210.84-0.890.306.17NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Share Based Compensation 4.794.394.834.745.125.305.275.416.366.075.295.265.835.104.495.495.404.883.804.354.574.163.433.684.003.603.463.043.003.123.002.222.101.901.630.990.860.780.610.470.140.110.140.21NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Investing Activities -33.52-113.4828.09-5.7971.9523.04-18.48-13.55-2.6213.82-34.26-16.07-43.2841.0110.567.63-6.37-10.12-70.4945.07NANANANANANANANANANANANANANANANANANANA-0.92NANANA-0.41NANANA
Payments To Acquire Property Plant And Equipment 0.500.290.360.390.801.011.421.382.132.070.633.560.500.591.251.250.780.591.680.714.225.5014.5210.769.857.301.491.061.985.512.832.782.612.811.001.660.670.790.450.921.160.450.430.41NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Financing Activities 49.910.06100.121.360.000.260.040.8018.972.35100.661.1074.0699.020.160.300.040.63119.000.47NANANANANANANANANANANANANANANANANANANA85.02NANANA0.00NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Revenues 10.4013.1424.5073.1041.7326.0111.1014.1515.6630.7616.8852.6918.2520.2613.6825.1918.7410.599.6615.7920.8018.834.70152.361.661.672.065.113.2580.672.858.1814.686.7271.285.4818.389.2214.7214.9120.2312.3010.609.8016.0817.4320.51
Incyte Corporation, Revenues From C M O Agreements Member 4.501.603.603.601.104.00NANA1.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
National Institute Of Allergy And Infectious Diseases, Revenues From Grants 0.300.500.300.400.500.500.400.500.100.400.800.900.804.600.700.700.800.600.20NA0.200.200.20NA0.400.40NANANANANANANANANANANANANANANANANANANANANA
Provention Bio, Royalty 0.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Incyte Corporation, Revenues From License Agreements, Incyte M G A012 Agreement 0.00NANA0.0030.00NANANANANANANANANANA-13.004.90NANA-131.206.10NANANANANANANANANANANANANANANANANANANANANANANANANANA
Incyte Corporation, Revenues From License Agreements, Incyte M G A012 Agreement Clinical Activities NANA15.00NA30.00NANANANANANANANA0.000.00NA0.000.000.10NA10.500.602.50NANANANANANANANANANANANANANANANANANANANANANANANA
Incyte Corporation, Revenues From License Agreements, Incyte M G A012 Clinical Services 0.200.101.30NA0.100.200.30NA0.200.700.100.500.701.505.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Incyte Corporation, Revenues From License Agreements, Incyte M G A012 Supply Agreement NANANANA0.000.30NANA1.402.803.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Janssen Biotech Inc, Revenue From Performance Of The Research And Development Activities, Janssen Collaboration And License Agreement NANANA0.100.100.200.300.400.200.600.30NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Gilead, A2022 Gilead Collaboration And License Agreement 0.400.200.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Gilead, Gilead First Research Program 0.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
I Mab Biopharma, I Mab Biopharma Collaboration And License Agreement NANANA0.003.800.600.208.201.001.700.60-1.401.001.401.101.201.100.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
I Mab Biopharma, I Mab Biopharma Collaboration And License Agreement Clinical Supply NANANA-0.900.300.300.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Zai Lab, A2018 Zai Lab Collaboration And License Agreement NANANA0.00-0.500.405.00NANANANANANANA4.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Zai Lab, A2021 Zai Lab Agreements NANANA0.001.8014.700.302.203.7014.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Zai Lab, Zai Lab Clinical Supply Agreements NANANA0.100.000.100.200.500.600.501.100.800.500.301.00NA1.200.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Provention Bio, Provention P R V031, Asset Purchase Agreement NANA0.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofi, Subsequent Event NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Contract Manufacturing 4.461.593.628.851.143.99NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Revenue From Collaborative Agreements 0.896.0216.6959.6735.6716.867.098.9611.9927.1715.1851.7517.4115.6412.9724.5617.989.999.5014.9720.6218.554.50152.081.081.08NANANANANANANANANANANANANANANANANANANANANA
Revenue From Government Agreements 0.340.470.280.470.550.480.430.520.090.390.810.940.844.620.710.640.760.610.170.820.180.280.190.280.590.58NANANANANANANANANANANANANANANANANANANANANA
Revenue From Royality Agreements Member 0.01-0.000.42NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product 4.705.063.494.104.374.673.584.673.593.200.89NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Interest Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Inventory Net
Current Assets
Inventory Net
NonCurrent Assets
Other Assets Noncurrent
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Operating Lease Liability
Current Liabilities
Accounts Payable Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
Shares
Weighted Average Number Of Shares Outstanding Basic
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Year Two
InventoryNet
Inventory Finished Goods

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:IncyteCorporation', 'mgnx:RevenuesFromLicenseAgreements', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:IMabBiopharma', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:ZaiLab', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel
(None, 'us-gaap:FairValueInputsLevel2')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Fair Value Hierarchy Level
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueMeasurementsRecurring')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Measurement Frequency
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:StatementEquityComponents
(None,)
Stock Issued During Period Value New Issuesus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:IncyteCorporation', 'mgnx:RevenuesFromLicenseAgreements', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:IMabBiopharma', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
('mgnx:ZaiLab', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type